TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate stable Chronic Obstructive Pulmonary.~* Disease with FEV1/FVC \<0.7 at screening.~* Woman of non-childbearing potential.~* Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth control during the study and for at least 1 month after completion of study dosing.~* Female participants must not be breastfeeding.~* Men must agree to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after completion of study dosing.~* Current or past smoking history \>10 pack-years.~* Must be capable of performing reproducible spirometry maneuvers.~Exclusion Criteria:~* History of significant respiratory disease other than COPD, and/ or requires daily long-term oxygen therapy.~* Exacerbation of COPD, lung infection within 6 weeks prior to study.~* Start of or change in dose of COPD treatment 4 weeks before study.~* Daily using of maintenance systemic/inhaled corticosteroids (\>1000 microgram of fluticasone propionate equivalent or \>5 mg prednisone).~* Use of bronchodilators or medication for the treatment of COPD, aspirin, anti-inflammatories for a specific time, prior to the first dose or is not willing to abstain from their use for the specified time periods prior to study dose administration.~* Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow angle glaucoma.~* Clinical significant hypersensitivity to medications.~* Participants have an uncontrolled hematologic, immunologic, renal, neurologic, hepatic, endocrine or other disease that may place participant at risk.~* Cerebrovascular, cardiovascular disease or abnormal ECG.~* History of drug or alcohol abuse.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
- Sequence 2 (Type: EXPERIMENTAL): Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
- Sequence 3 (Type: EXPERIMENTAL): Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
- Sequence 4 (Type: EXPERIMENTAL): Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress~* Current depressive episode must be at least 8 weeks in duration~Exclusion Criteria:~* Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome~* Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode~* Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole + ADT (Type: EXPERIMENTAL): Brexpiprazole + ADT
- Placebo + ADT (Type: PLACEBO_COMPARATOR): Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists status 1 to 4~* Scheduled laparoscopic surgery~* Standardized anesthesia (TCI)~* Social security affiliation~Exclusion Criteria:~* Age \< 18 yrs old~* Emergency~* BMI ≥ 35 kg.m-2~* Refusal of consent~* History of ocular pathology~* Intake of: metoclopramide, droperidol, opioids or substitutive therapies~* Patient with chronic pain~* Neurologic impairments~* Neuropathic pain~* Drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pupillometry guided analgesia (PP) (Type: EXPERIMENTAL): Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
- Standard practice (ST) (Type: NO_INTERVENTION): Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients on CHD for more than 3 months;~2. Ability to read and sign the consent form;~3. Have acceptable dialysis adequacy (Kt/V \> 1.2);~4. Use biocompatible hemodialysis membrane;~5. Have a patent, well functioning, arteriovenous dialysis access;~6. Signs of chronic inflammation (the average of three consecutive CRP measurements ≥ 5 mg/L).~Exclusion Criteria:~1. Patients with residual renal function \> 5 ml/min or urine output \> 100 ml/day;~2. Pregnancy;~3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);~4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);~5. Hospitalization within 1 month prior to the study;~6. Malfunctioning arterial-venous vascular access \[recirculation and/or blood flow \< 500 ml/min for an arterial-venous graft (AVG) or \< 400 ml/min for an arterial-venous fistula (AVF)\];~7. Patients receiving steroids and/or other immunosuppressive agents;~8. Life-expectancy less than 6 months;~9. Age greater than 75 or less than 18 years old;~10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.~11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Kineret (Type: ACTIVE_COMPARATOR): Interleukin-1 receptor antagonist
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Registered in the project census~* Age \>=2 years~* Provide informed consent to receive vaccine~Exclusion Criteria:~* Fever (\>37.5 degrees Celsius)~* Pregnancy~* Lactating

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Typhoid Vi vaccine
- 2 (Type: ACTIVE_COMPARATOR): Hepatitis A vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scenario Tailored Opioid Messaging Program (STOMP) to Improve Risk Understanding in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing an elective surgical procedure for which it is expected they will receive a prescription pain medicine for management of pain during recovery at home.~Exclusion Criteria:~* Undergoing non-elective procedure~* Cognitive impairment precluding self-reporting of pain~* Hematologic/oncologic condition~* Liver of kidney conditions precluding usual analgesic prescription patters (opioid plus a non-opioid)~* Use of opioids for prolonged pain pre-operatively (\<2 weeks)

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Education Intervention (Type: EXPERIMENTAL): This group will receive the scenario-tailored STOMP educational feedback
- Control (Type: NO_INTERVENTION): This group will receive only standard of care information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mirabegron and Urinary Urgency Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bothersome idiopathic (non-neurologic) urgency urinary incontinence (UUI) who recall ≥ 5 urgency predominant urinary incontinence episodes in the prior week (urgency urinary incontinence or mixed urinary incontinence-urgency predominant)~* No contraindications to taking mirabegron~* Patients on current OAB therapy will undergo a two-week drug washout period prior to baseline assessment~Exclusion Criteria:~* Neurologic disease known to affect the lower urinary tract~* Systemic immunologic deficiency~* Current urinary tract infection (UTI) (based on dipstick assessment) or recurrent culture-proven UTIs~* History or current pelvic malignancy or radiation~* Untreated symptomatic pelvic organ prolapse (POP) \> POP-Q Stage II~* A contraindication to receiving mirabegron~* Women of childbearing potential who are pregnant or nursing or intend to become pregnant during the study, or who are not practicing a reliable method of contraception~* Must not have taken any antibiotics in the 4 weeks prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirabegron (Type: EXPERIMENTAL): Participants received mirabegron (Myrbetriq) daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Berinert P Study of Subcutaneous Versus Intravenous Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with an established diagnosis of HAE type I (C1-Inhibitor activity \< 50% and C1-Inhibitor antigen \< 15.4 mg/dl) or HAE type II (C1-Inhibitor activity \< 50% and C1-Inhibitor antigen in normal or elevated concentration of dysfunctional protein).~* Male and female subjects with an age of at least 18 years.~* Subjects providing an informed consent.~Exclusion Criteria:~* Subjects without an established diagnosis of HAE.~* Last C1-INH administration less than 7 days ago and/or acute attack.~* Subjects with acquired angioedema (AAE).~* All other types of angioedema not associated with C1-INH deficiency.~* Treatment with any investigational drug (exclusive drugs appropriate for the treatment of acute angioedema) 30 days before study treatment.~* Treatment with any other drug appropriate for the treatment of acute angioedema within 7 days before start of study treatment at each phase.~* Danazol prophylaxis.~* Prophylaxis with antifibrinolytics, EACA, tranexamic acid.~* Subjects with a known hypersensitivity to study medication (Berinert P).~* Pregnant women (pregnancy rapid assay required for women with childbearing potential), women currently breast-feeding, or with the intention to breast-feed~* Subjects with malignant diseases.~* Subjects with immunodeficiencies such as established acquired immunodeficiency syndrome.~* Subjects with concurrent serious or acute illness or infection as per investigators judgement.~* Subjects with mental conditions which render the subject or its legally acceptable representative unable to understand the nature, scope and possible consequences of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
- 2 (Type: ACTIVE_COMPARATOR): subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female of at least 15 months of age at the time of the booster vaccination, who had previously received 3-dose primary vaccination and, if applicable, plain-PRP vaccination.~* Free of obvious health problems as established by medical history and clinical examination before entering the study.~Exclusion criteria for enrolment~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before and ending 30 days after administration of study vaccines with the exception of oral polio vaccine (OPV).~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.~* Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B or Hib with the exception of plain PRP challenge.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein~* Ability to comprehend and sign an informed consent document and complete study questionnaires in English~* Ability to record symptoms in accordance with the protocol~* Symptomatic varicose veins~* Visible varicose veins~Exclusion Criteria:~* Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP (clinical, etiologic, anatomic, and pathophysiologic) Classification of Venous Disorders).~* Leg obesity impairing the ability to access the vein to be treated and/or to apply postprocedure compression bandaging and stockings~* Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion~* Deep vein reflux unless clinically insignificant in comparison to superficial reflux~* Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings~* Reduced mobility~* Major surgery, prolonged hospitalization or pregnancy within 3 months of screening~* Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)~* Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions~* Current alcohol or drug abuse~* Pregnant or lactating women~* Women of childbearing potential not using effective contraception~* History of DVT, pulmonary embolism or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Polidocanol injectable foam 0.125% (Type: EXPERIMENTAL): Polidocanol injectable foam 0.125%
- Polidocanol injectable foam 0.5% (Type: EXPERIMENTAL): Polidocanol injectable foam 0.5%
- Polidocanol injectable foam 1.0% (Type: EXPERIMENTAL): Polidocanol injectable foam 1.0%
- Polidocanol injectable foam 2.0% (Type: EXPERIMENTAL): Polidocanol injectable foam 2.0%
- Vehicle (Type: PLACEBO_COMPARATOR): Injection of vehicle comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained from the subject and/or his/her legally authorised representative (LAR) before any trial-related activities~* Injury(ies) due to a blunt and or penetrating trauma~* Receipt of 6 units of PRBC within a 4 hour period following admittance to the trauma centre~* Receipt of 8 units of PRBC upon administration of trial drug~Exclusion Criteria:~* Prehospital cardiac arrest~* Cardiac arrest in the ER or OR~* Gunshot wound to the head~* Glasgow Coma Scale below 8~* Base deficit of above 15 mEq/l or severe acidosis~* Transfusion of 8 units or more of PRBC prior to arrival in trauma centre

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Activated recombinant human factor VII (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients in pediatric intensive care unit~Exclusion Criteria:~* Patients with a history of an allergic reaction to chlorhexidine~* Patients less than 2 months of age~* Patients with severe skin disease or burn~* Patients with an indwelling epidural catheter or lumbar drain

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Daily bathing with 2% chlorhexidine gluconate
- 2 (Type: NO_INTERVENTION): Standard bathing with soap and water basin or disposable cloth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: 1.All stroke patients with parietal lobe and thalamic lesions 2. Stroke duration: within 48 hours 3. Patients willing to participate in the study 4. MRI/ CT scan showing parietal lobe and thalamic lesion 5. Patients with upper limb weakness~Exclusion Criteria:~1. Stroke duration more than 1 yr~2. Glasgow Coma Scale (GCS) of less than 7~3. Uncooperative patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirror therapy (Type: EXPERIMENTAL): All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
- Control group (Type: SHAM_COMPARATOR): Group 2 will be given sham mirror therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete